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Introduction
Piperacilin-tazobactam (TZP) and meropenem (MER)
are two extended-spectrum beta-lactams antibiotics
(ATB) broadly used in intensive care units. We know
that early and appropriate ATB treatment remains the
most important intervention in septic patients, so opti-
mization of ATB administration should be a priority.
Objectives
Evaluate the effectiveness of MER and TZP administered
in continuous infusion in critically ill patients in order
to maintain concentrations 4-6 times above the mini-
mum inhibitory concentration (MIC) for 100% of the
interval time of infusion.
Methods
Open, prospective, single-center study. All consecutive
patients in whom treatment with MER or TZP was indi-
cated from October 2014 to March 2015 were included.
A 2g (MER) or 4g (TZP) loading dose was given fol-
lowed by a 6g (MER) or 16-24g (TZP) continuous infu-
sion over 24 hours. Serum concentrations were
determined by high-performance liquid chromatography
(HLPC) 1 hour, 24 hours and 3-5 days after the start of
the infusion, determining maximum (Cmax) and free
steady state concentrations (ƒCss). The objective was
maintaining ƒCss 4-6 times above the MIC correspond-
ing to the clinical breakpoint for Pseudomonas aerugi-
nosa from our hospital database: 8 µg/ml for MER and
16/4 µg/ml for TZP. When the target was not achieved,
the dose was adjusted.
Results
We enrolled 49 patients (73% male and 27% female) and
determined 60 Css. Mean APACHE-II score was 16 ± 7.
Empiric therapy was administered in 48 cases (80%).
13 patients (26%) were admitted to ICU after ≥ 7 days
of hospitalization. 25 patients (51%) had septic shock,
2 (4%) severe sepsis and 1 (43%) sepsis. 1 patient (2%)
had not systemic inflammatory response (SIR). 9 patients
(18%) had bacteremia. We analyzed Css of MER/TZP
during the first 24-48 hours, which are shown in Table1.
Css determination led to the dose titration in 30% of the
treatments.
Conclusions
Although ATB optimization, 32% of patients did not
achieve our outcome. Therapeutic drug monitoring
allows us to adjust dose administrated based on Css in
order to achieve optimal drug exposure for an individual
patient. Based on our results, dosages needed in criti-
cally ill patients might be markedly higher than those
currently administered. We remark the need to keep
analyzing cases to assess risk factors for ATB underdos-
ing and continue monitoring Css to evaluate further
dose adjustments.
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Table 1. Css within the first 24-48 hours
antibiotic Cases ƒCss < 4MIC ƒCss 4-10 MIC ƒCss >10 IMC
Meropenem 2 g 14 6 (43%) 7 (50%) 1 (7%)
Piperacilin-tazobactam 16g 15 2 (13 %) 9 (60%) 4 (27%)
Piperacilin-tazobactam 24g 31 11 (35%) 16 (52%) 4 (13%)
Total 60 19 (32%) 32 (53%) 9 (15%)
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